4.1 Article

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

期刊

ANTIVIRAL THERAPY
卷 16, 期 2, 页码 253-256

出版社

INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1748

关键词

-

资金

  1. Bristol-Myers Squibb
  2. Cerner Corporation
  3. Gilead Sciences
  4. Merck
  5. Roche
  6. GlaxoSmithKline
  7. Boehringer Ingelheim

向作者/读者索取更多资源

We report the case of an integrase strand-transfer inhibitor (INI)-resistant and four-drug-class-resistant HIV-1 variant infecting an antiretroviral therapy-naive man. The virus harboured INI drug resistance substitutions (Q148H and G140S) along with multiple reverse transcriptase and protease inhibitor resistance mutations. This case illustrates an emerging need to consider the possibility of acquired INI resistance among newly diagnosed treatment-naive individuals harbouring multidrug-resistant HIV-1.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据